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A B S T R A C T
This investigation profiled circulating serum concentrations of microRNAs (miRNAs) in premature cardiovas-
cular disease (CVD) patients screened for the 677C > T polymorphism in methylenetetrahydrofolate reductase
(MTHFR), a risk factor for hypertension. Serum samples from 75 premature CVD patients of known MTHFR
genotype were analysed for CVD-related miRNA expression, to identify those that were associated with blood
pressure. Samples were collected at baseline and following intervention with riboflavin as part of a randomized
controlled trial. In patients with the MTHFR 677TT genotype, expression of miR-199a-5p in serum was inversely
correlated with hypertension at baseline, and with change in blood pressure in TT genotype patients who re-
sponded to riboflavin intervention. These correlations were not observed in MTHFR 677CC genotype patients. In
vitro experiments and in silico data analysis provided evidence that miR-199a-5p targets SMAD4. This is the first
study to link miR-199a-5p expression with hypertension in a genetically at-risk cohort of premature CVD pa-
tients.
1. Introduction
Cardiovascular diseases (CVD) are among the leading causes of
morbidity and mortality globally [1]. At present elevated blood pres-
sure is the most important predictor of vascular mortality [2], but the
underlying causes of hypertension remain unclear. It is becoming in-
creasingly apparent that genetic traits influence the biological processes
causing hypertension, leading to the suggestion that specific genetic
markers may offer a novel diagnostic approach to inform therapeutic
interventions to reduce CVD incidence [3,4]. A new class of genes
called microRNAs (miRNAs) have generated much excitement in this
respect and show great potential for early diagnosis and tailored
treatment for CVD [4–7].
miRNAs are small, non-coding RNA molecules that regulate gene
expression by interacting with messenger RNAs (mRNAs). Preliminary
studies provide some evidence that the abnormal expression of miRNAs
is associated with various degenerative disease states, including CVD
[4–6]. Both animal and human studies have identified circulating
serum concentrations of different miRNAs as potentially valuable
markers of acute myocardial infarction [7], heart failure [8,9], cardiac
hypertrophy [10], stroke [11,12], and hypertension [9,13]. However,
the reported findings are often based on relatively small samples, with
contradictory results reported between studies; thus it is still not certain
which miRNAs are the most reliable biomarkers, or which ones exert
most influence in CVD development. It is clear that more focused stu-
dies are required in order to identify miRNAs which play an important
role in CVD progression and to understand how they function. To ad-
dress this need, we considered how variation in the gene encoding the
folate-metabolizing enzyme methylenetetrahydrofolate reductase
(MTHFR) may contribute to hypertension by influencing the epigenetic
regulation and subsequent expression of miRNAs.
The 677C > T polymorphism in the MTHFR gene encoding for
MTHFR is associated with an increased risk of CVD, particularly stroke
[14–16]. More recently this genetic variant has emerged as an
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independent risk factor for hypertension, with meta-analyses estimating
an increased risk of between 24 and 87%, specifically in adults who are
homozygous for the polymorphism (MTHFR 677TT genotype) [17].
Importantly, MTHFR activity is dependent on an adequate supply of the
B-vitamin riboflavin in its co-factor form FAD. Previous work conducted
at this centre has demonstrated in 3 separate randomized controlled
trials (RCTs) that intervention with riboflavin at the dietary level of
1.6 mg/day can significantly decrease blood pressure in TT hyperten-
sive adults compared with controls [18–20]; no such decrease in blood
pressure was observed in the CT or CC genotypes compared with con-
trols [18]. The mean lowering of blood pressure observed across the
three studies ranged from 5 to 13mmHg [17] and although the me-
chanism of action remains to be established, it has been suggested that
epigenetic modification may be implicated [21]. This modification
could lead to aberrant expression of important genes, including
miRNAs.
No previous study has considered how miRNA expression might be
influenced by MTHFR genotype. Therefore, this study was intended as a
proof-of-principle pilot study to address this gap in the knowledge. The
aim was to investigate if miRNA expression differs with MTHFR geno-
type and can be modified in patients whose blood pressure had re-
sponded significantly to riboflavin treatment, by analyzing samples
from our previously conducted RCTs [18–20]. In doing so, we aimed to
explore how miRNAs might be influenced by changes in blood pressure,
which would in turn provide insights to the underlying pathogenesis of
CVD.
2. Materials and methods
2.1. Clinical serum samples
The set of serum samples analysed in this study had been collected
from premature CVD patients with knownMTHFR genotype, as part of a
previous larger study at Ulster University [18]. Patients were recruited
from Altnagelvin Area Hospital, Western Health and Social Services
Trust, Northern Ireland, and screened for the 677C > T polymorphism
in MTHFR (rs1801133) by DNA analysis of a buccal swab sample. CVD
was identified by a previous myocardial infarction diagnosed on the
basis of ECG changes or angina diagnosed by an exercise stress test.
Recruited patients were subsequently randomized to treatment as part
of a placebo-controlled double-blind, randomized controlled riboflavin
trial. As previously described [18], blood pressure measurements were
recorded and non-fasting blood samples were collected at baseline and
post-intervention by the same researcher blinded to the genotype and
treatment status of the patient. At each time point, two separate mea-
surements were taken 15min apart, with the patient at rest (10–15min)
in the sitting position, using an Omron 705CP electronic blood pressure
monitor (Medisave, Dorset, UK). Weight (kg), height (m), BMI (weight
(kg)/height2 (m)) and waist circumference (cm) were also recorded.
Plasma total homocysteine and red cell folate pre- and post-intervention
were subsequently measured. Similarly, riboflavin status was de-
termined by erythrocyte glutathione reductase activity coefficient
(EGRac). Ethical approval was granted by both the Research Ethical
Committee at Ulster University and Altnagelvin Area Hospital. All pa-
tients completed a health and medical/lifestyle questionnaire and
provided informed consent for their tissues to be used in subsequent
studies. Use of patient material and information, as well as research
protocols, were approved by ORECNNI (Ref. No. 12/NI/0136). For the
current study, all available TT samples from the original cohort were
used (45 out of 49). 30 matched samples from CC genotype patients
were selected for comparison.
2.2. microRNA expression profiling
The FirePlex miRNA Assay (Abcam, Cambridge, UK) was used to
profile miRNAs in each serum sample. The Cardiology Fixed Panel
contained 68 miRNAs that have been previously reported to be differ-
entially regulated in normal or abnormal cardiovascular health
(Supplementary Table 1). The panel included general markers for
multiple cardiovascular-related diseases, markers specific to specific
cardiovascular states or treatment responses, markers that may indicate
haemolysis in isolated plasma/serum/exosomes and internal controls to
validate assay performance. Results were obtained as flow cytometric
fluorescent readouts which were normalized as part of the data ana-
lysis.
2.3. Cell culture & transfections
Human Umbilical Vein Endothelial Cells (HUVEC) cell-line was
obtained from the American Type Culture Collection (ATCC, Rockville,
MD, USA). Cells were cultured in ATCC-formulated F-12 K (Kaighn's
Modification of Ham's F-12 with L-glutamine) growth medium (ATCC)
supplemented with 0.1 mg/ml heparin and 0.03mg/ml endothelial cell
growth supplement (ECGS) (both Sigma-Aldrich) and adjusted to a final
concentration of 10% Fetal Bovine Serum (Life Technologies). Prostate
epithelial cell-line RWPE1 was cultured in keratinocyte growth medium
supplemented with 5 ng/ml human recombinant epidermal growth
factor and 0.05mg/ml bovine pituitary extract (Life Technologies,
Paisley, UK). All cells were grown on gelatine (Sigma-Aldrich) coated
tissue culture flasks and plates in an incubator with a humidified at-
mosphere of 95% air and 5% CO2 at 37 °C and routinely passaged. For
miRNA transfection, cells were seeded at 100,000 cells/well in a 6-well
plate. After 24 h, cells were transfected with miR-199a (pre-miR-199a-
5p) or non-targeting negative control (pre-neg) (both Life Technologies)
at a final concentration of 25 nM using Lipofectamine 2000 (Life
Technologies). After 72 h, cells were harvested for RNA extraction.
2.4. PCR analysis
RNA extraction was carried out using Trizol (Life Technologies)
according to manufacturer's instructions. For gene analysis, 1 μg RNA
was used for first strand cDNA synthesis using random primers with
transcriptor high-fidelity cDNA synthesis kit (Roche, Sussex, UK) ac-
cording to manufacturer's instructions. For quantitative real-time PCR
(qRT-PCR), amplification of PCR products was quantified using
FastStart SYBR Green Master (Roche) on a Roche LC480 Lightcycler,
using primer sets for SMAD4 (Forward 5’-AAGGTTCCTTCAAGCTG
CCC-3′; Reverse 5’-CAATGGCTTCTGTCCTGTGGA-3′), VEGFα (Forward
5’-AGCTACTGCCATCCAATCGA-3′; Reverse 5’-GGTGAGGTTTGATCCG
CATA-3′), and housekeeping gene β-actin (Forward 5’-GGACTTCGAGC
AAGAGATGG-3′; Reverse 5’-AGCACTGTGTTGGCGTACAG-3′).
Expression was normalized to β-actin and graphs represent the
Table 1
Baseline characteristics of premature CVD patients (n=75) prescreened for the
MTHFR 677C > T genotype.
MTHFR 677C > T Genotype
CC (n=30) TT (n= 45)
Age now (years) 53.1 54.4
Age at event (years) 47.3 47.4
Male (%) 76.7 82.2
Family History of CVD (%) 73.3 68.9
Current Smoker (%) 30.8 33.3
BMI (kg/m2) 28.4 29.2
Waist Circumference (cm) 96.8 94.3
Blood Pressure
Systolic Blood Pressure (mmHg) 117.9 144.3***
Diastolic Blood Pressure (mmHg) 74.8 86.9***
Data are expressed as the mean unless otherwise indicated. Statistical sig-
nificance was assessed by one-way ANOVA with Tukey posthoc test (P-values:
*p < .05, **p < .01, ***p < .001).
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combined results of three independent biological replicates.
For microRNA analysis, qRT-PCR for miR-199a-5p was performed
using the miRCURY LNA™ microRNA PCR system (Exiqon, Vedbaek,
Denmark). 20 ng template RNA was used in each first strand cDNA
synthesis reaction. PCR was performed over 40 amplification cycles and
fluorescence monitored on the Roche LC480 Lightcycler. For all qRT-
PCR miRNA analysis, normalization was against U6snRNA and graphs
represent the combined results from 3 independent biological re-
plicates, unless otherwise indicated.
2.5. Statistical analysis
One-way ANOVA with Tukey posthoc test or unpaired two-tailed
Student's t-test was used to compare baseline characteristics among the
genotype groups. The response to riboflavin intervention was examined
by conducting a within–between repeated measures ANOVA for both
systolic and diastolic blood pressures (mmHg). The between patient
factors were genotype (CC vs TT) and intervention group (placebo vs
riboflavin) with time (before and after) as the within-patient factor.
Adjustments for multiple comparisons using Bonferroni were in-
corporated in the analyses. The FirePlex Analysis Software package
(Abcam) was used to analyse miRNA expression. Normalization of all
sample data was performed using the geNORM algorithm. The three
optimal normalizers identified (let-7i-5p, miR-16-6p and miR-92a-3p)
were combined into a single normalization vector which was subse-
quently applied across the entire dataset. Subsequent analysis of nor-
malized data was performed by Pearson's two-tailed correlation, two-
tailed Student's t-test and ANOVA with Tukey posthoc test. In all
analyses p-value thresholds of ***p < .001, **p < .01, *p < .05 were
applied. Data-mining, network mapping, KEGG pathway and Gene
Ontology analysis was performed using statistical resources freely
available through miRTarbase (http://mirtarbase.mbc.nctu.edu.tw/
index.php [22] and the Database for Annotation, Visualization and
Integrated Discovery (DAVID) bioinformatics resource (http://david.
ncifcrf.gov/) [23,24].
3. Results
3.1. Baseline characteristics of premature CVD patients
The pre-intervention baseline characteristics of participants
(n=75) by MTHFR genotype, included in the current analysis is shown
in Table 1. In this subset of 75 samples, we confirmed that the patients
with the TT genotype had a significantly higher systolic (p < .001) and
diastolic blood pressure (p < .001) at baseline compared to the CC
genotype (Fig. 1a), in accordance with findings from the previous study
[18].
3.2. Blood pressure response to riboflavin intervention
When the samples selected for the current investigation were split
into those obtained from patients in the placebo or riboflavin treatment
groups, a significant decrease in both systolic (-10mmHg) and diastolic
(-8 mmHg) blood pressure following intervention with riboflavin was
observed in patients with TT genotype, whereas no significant reduc-
tion was evident in the CC genotype group (Table 2, Fig. 1b and c). The
extent of the blood pressure response and the genotype-specific effect of
riboflavin were similar to those effects reported previously in the larger
cohort [18].
3.3. Cluster analysis heat map of miRNA expression
The serum expression of 68 miRNAs was profiled using a cardiology
focus panel. Patients were grouped into their respective MTHFR geno-
type and a cluster analysis heat map was used to illustrate the relative
expression levels of each miRNA following normalization
(Supplementary Fig. 1a). In all samples miRNA expression was suc-
cessfully measured and profiled. No overall differences were noted
between expression of any individual miRNA in the CC and TT geno-
type groups. However, it was noted that miR-199a-5p had a fold in-
crease of 1.47 in TT genotype samples compared to CC genotype sam-
ples, although this fell just short of statistical significance (p= .053)
(Supplementary Fig. 1b). Therefore, its expression was examined in
more detail.
Fig.. 1. Blood Pressure in Premature CVD Patients Pre- and Post- Intervention with Riboflavin.
(a) In pre-intervention samples, patients with the TT genotype have a significantly higher systolic and diastolic blood pressure at compared to the CC genotype.
Following riboflavin intervention (1.6mg per day, 16 weeks), patients with the TT genotype had a significant decrease in both (b) systolic and (c) diastolic blood
pressure in comparison to patients with the CC genotype. These findings were in keeping with those of the original study [18]. Statistical significance was assessed by
paired two tailed t-test. (P-values: *p < .05, **p < .01, ***p < .001).
Table 2
Blood pressure response to riboflavin intervention (1.6mg per day, 16 weeks).
MTHFR 677C > T Genotype
CC (n= 30) TT (n=45)
Placebo Riboflavin Placebo Riboflavin
Systolic Blood Pressure (mmHg)
Before 112.8 123 146.6 142
After 117.8 128.5 142.7 132
Change +5 +5.5 −3.9 −10*
Diastolic Blood Pressure (mmHg)
Before 73.1 76.5 85.7 88
After 76.1 78.8 85.7 81
Change +2.9 +2.3 0 −8**
Data are expressed as the mean unless otherwise indicated. Statistical sig-
nificance was assessed by paired two tailed t-test. (P-values: *p < .05,
**p < .01, ***p < .001).
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3.4. Correlation of miR-199a-5p expression with blood pressure
The expression of miR-199a-5p was of interest as previous reports
suggest a link between miR-199a-5p and hypertension [25–27]. In this
study a correlation of miR-199a-5p expression with systolic blood
pressure in all 75 patients revealed only a slight trend towards an in-
verse correlation (Fig. 2a). However, when this analysis was confined to
patients with the TT genotype, a highly significant inverse correlation
was observed (Fig. 2b). Further correlation of miR-199a-5p expression
with blood pressure in patients in the highest systolic blood pressure
tertile (n=15; mean=165 ± 10.17mmHg) and the lowest tertile
(n=15; mean=123 ± 10.93mmHg) was performed. This sub-group
analysis revealed that TT genotype patients with higher systolic blood
pressure showed significantly lower levels of miR-199a-5p expression
than those TT genotype patients with lower systolic blood pressure
(Fig. 2c).
A similar inverse correlation was observed in relation to diastolic
blood pressure. A slight trend towards an inverse correlation was evi-
dent in all patients (Fig. 2d), but this became significant when analysis
was confined to the TT genotype patients only (Fig. 2e). Similarly, the
TT genotype patients in the highest tertile of diastolic blood pressure
(n=15; mean=100 ± 5.72mmHg) showed significantly lower levels
of miR-199a-5p expression than those TT genotype patients in the
lowest tertile of diastolic blood pressure (n= 15; mean=74 ±
7.85mmHg) (Fig. 2f). It is worth noting that in CC genotype patients, a
positive correlation was shown between miR-199a-5p expression and
systolic blood pressure (Supplementary Fig. 2a). However, no sig-
nificant correlation was observed for miR-199a-5p expression and
diastolic blood pressure (Supplementary Fig. 2b), nor was any sig-
nificant difference in miR-199a-5p expression noted when samples from
patients with highest and lowest blood pressure tertiles in this cohort
were compared (Fig. 2c and f).
3.5. Correlation of miR-199a-5p Expression with Blood Pressure in
Response to Riboflavin Intervention in Patients with TT genotype
Given the inverse correlation observed above, the question re-
mained as to whether the reduction in blood pressure observed in re-
sponse to riboflavin intervention in the TT genotype patients would be
accompanied by increased expression of miR-199a-5p expression in
individual patients. To examine this, it was necessary to filter the TT
genotype cohort to focus on ‘TT responders’. When the change in ex-
pression of miR-199a-5p was correlated with the change in systolic
blood pressure in the TT genotype cohort as a whole (n=45), only a
trend towards an inverse correlation was revealed (Fig. 3a). Notably,
this inverse trend was more evident in TT genotype patients treated
with riboflavin (n=23) (Fig. 3b), whereas no trend towards an inverse
correlation was observed at all in TT patients treated with placebo
(n=22) (Fig. 3c). When the riboflavin group were further filtered to
analyse only the patients who showed a decrease in systolic blood
Fig. 2. Correlation of miR-199a-5p Expression with Blood Pressure.
(a) A slight trend to inverse correlation was observed for miR-199a-5p with systolic blood pressure in all patients (n=75) prior to intervention. (b) This inverse
correlation became highly significant in patients with TT genotype (n= 45). (c) TT patients in highest tertile of systolic BP (n=15: mean= 165 ± 10.17mmHg)
showed significantly lower levels of miR-199a-5p than those in the lowest tertile (n= 15: mean= 123 ± 10.93mmHg). No significant difference in miR-199-5p
expression was noted when the same analysis was performed on CC patients in the highest (n=10: mean=128.1 ± 4.88 mmHg) and lowest (n= 10:
mean= 106.6 ± 7.76mmHg) tertile of systolic BP. (d) - (f) A similar inverse correlation was observed between miR-199a-5p and diastolic BP. TT patients in highest
tertile of diastolic BP (n= 15: mean= 100 ± 5.72mmHg) showed significantly lower levels of miR-199a-5p than those in the lowest tertile (n= 15:
mean= 74 ± 7.85mmHg). No significant difference in miR-199-5p expression was noted for CC patients in the highest (n=10: mean= 65 ± 6.50mmHg) and
lowest (n=10: mean= 84.7 ± 4.00mmHg) tertile of diastolic BP. Significance was assessed by Pearson's two tailed correlation (A, B, D, E) or one-way ANOVA
with Tukey posthoc test (C & F). (P-values: *p < .05, **p < .01, ***p < .001, ns; no significance).
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pressure in response to riboflavin intervention (n=14), a significant
inverse correlation was noted (Fig. 3d). Linear regression analyses
corroborated these results (Supplementary Fig. 3). Thus, in these TT
responders, those who responded with the greatest decrease in blood
pressure had the greatest increase in miR-199a-5p expression, although
the mechanisms underlying these changes are unknown. Therefore,
further in vitro and in silico work was performed to explore what these
mechanisms might be.
3.6. Role of miR-199a-5p in hypertension
The role of miR-199a-5p in hypertension has not been extensively
studied, but several target genes for miR-199a-5p have been identified.
To examine how miR-199a-5p might contribute to hypertension,
functional annotation analysis of these target genes was performed
using the DAVID Bioinformatics Resource [23,24]. Importantly, many
miR-199a-5p target genes were revealed to be significantly associated
with CVD and hypertension (Supplementary Table 2). Further gene
ontology analysis demonstrated a significant association between these
targets and cellular processes related to cardiac and vascular develop-
ment, again illustrating how abnormal expression of miR-199a-5p could
influence CVD progression through altered regulation of its target genes
(Supplementary Table 3). Likewise, KEGG pathway results revealed a
significant enrichment of miR-199a-5p target genes in cellular me-
chanisms which have been implicated in development of hypertension
(Supplementary Table 4) [28–33]. To further investigate novel func-
tionality of this miRNA, its specific impact upon selected target genes
was examined (Fig. 4). Interestingly, one predicted target gene of miR-
199a-5p was SMAD4 (Supplementary Table 4, Fig. 4a), which has been
previously implicated in hypertension [27,34]. To validate this poten-
tial link, miR-199a-5p was over-expressed in HUVEC cells and the effect
on SMAD4 expression measured by PCR. As expected, SMAD4 expres-
sion was significantly reduced when miR-199a-5p levels were in-
creased, which would be expected if SMAD4 was a true target of miR-
199a-5p (Fig. 4b). As a control, expression of VEGFA, a more estab-
lished target of miR-199a-5p [35,36] was examined and was also found
to be decreased by miR-199a-5p over-expression. A similar reduction of
SMAD4 expression was observed when we repeated this experiment in
RWPE1 epithelial cells (Supplementary Fig. 4a). Further evidence that
miR-199a-5p targets SMAD4 comes from two independent datasets,
generated from a study on human aortic valvular endothelial cells [37]
and from a cohort of prostate biopsy samples from The Cancer Genome
Atlas [38]. In both of these, a significant inverse correlation between
miR-199a-5p and SMAD4 expression is observed (Fig. 4c and Supple-
mentary Fig. 4b). Network analysis of this interaction demonstrated
how both miR-199a-5p and SMAD4 can also influence other genes
which contribute to hypertension (Fig. 4d).
4. Discussion
In this study we set out to investigate if miRNA expression differs
with MTHFR genotype and can be modified in patients whose blood
pressure had responded significantly to riboflavin treatment, by ana-
lyzing samples from our previously conducted RCTs [18–20]. We have
successfully demonstrated that we can measure and profile miRNA
expression in archived serum samples collected from premature CVD
patients. These patients were recruited as part of a previous study
which demonstrated that riboflavin supplementation could significantly
Fig. 3. Correlation of miR-199a-5p Expression with Blood Pressure in Response to Riboflavin Intervention.
Analysis of change in miR-199a-5p expression with change in systolic blood pressures in (a) the TT cohort as a whole (n=45) and (b) those treated with riboflavin
(n=23) revealed a trend towards inverse correlation. (c) No inverse correlation is apparent in placebo treated TT patients (n=22). (d) However, in patients who
responded to riboflavin intervention with a decrease in blood pressure (TT responders; n=14), a significant inverse correlation was observed. Significance in all
graphs was assessed by Pearson's two tailed correlation. (P-value: *p < .05).
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lower blood pressure in individuals with the MTHFR 677TT genotype
[18]. Thus, we had a unique set of archived serum samples, pre and
post a highly effective intervention, in which we could test whether any
circulating miRNAs correlated with change in blood pressure. From the
68 miRNAs analysed, miR-199-5p emerged as the most promising
candidate for further investigation.
As this was a pilot study, we had a relatively small set of samples to
work with, all of which were taken from at-risk CVD patients. A wide
variation in miRNA expression was noted, meaning no single miRNA
was differentially expressed in CC and TT genotype patients at baseline.
However, we did note that miR-199a-5p was increased in TT genotype
samples compared to CC genotype samples, even though this fell just
short of statistical significance; this observation was interesting because
miR-199a-5p had previously been linked with hypertension [25]. We
therefore proceeded to directly correlate miR-199a-5p serum expres-
sion and blood pressure. This analysis showed that expression of miR-
199a-5p at baseline was significantly inversely correlated with blood
pressure in the serum of MTHFR 677TT genotype patients. Moreover,
when pre- and post-intervention samples from MTHFR 677TT genotype
patients were analysed, an increase in miR-199a-5p expression was
inversely correlated with a decrease in blood pressure. In CC genotype
patients, these correlations were not apparent; only one significant
correlation between miR-199a-5p expression and systolic blood pres-
sure was observed. This suggests that the serum expression of miR-
199a-5p in MTHFR 677TT genotype patients is somehow linked to
hypertension only in the TT group of individuals, although the reasons
for this require further investigation.
Altered expression of miR-199a-5p is noteworthy as there is some
evidence that miR-199a-5p plays a role in CVD. One comprehensive
study showed how the hypoxia-inducible cluster miR-199a∼ 214,
which includes miR-199a-5p, was functionally linked to hypertension
and possible heart failure [25]. Upregulation of miR-199a-5p has been
reported in lung tissue from mouse and rat models of pulmonary artery
hypertension (PAH), firmly implicating it in the development of this
disease [26]. These results were corroborated by an independent study
of PAH in animal models, which also identified SMAD3 as a target of
miR-199a-5p [27]. Additionally, the expression of miR-199a-5p was
increased in the lung tissues of patients with chronic obstructive pul-
monary disease (COPD) [39], and similar results were shown in ven-
tricular hypertrophy diseases [10]. Further evidence of a link with
hypoxic stress comes from studies reporting that HIF-1a is a target of
miR-199a-5p [39,40], and suggests it may be a key regulator in the
cellular response to hypoxia. It therefore seems clear that miR-199a-5p
plays an important role in mechanisms linked to hypoxic stress and may
contribute to hypertension and pathogenesis of various CVD. In this
study, we provide further evidence for an important role for miR-199a-
5p in mechanisms related to vascular and cardiac processes. We also
identify SMAD4 as a likely target of miR-199a-5p by in vitro and in silico
analysis. This link is important because defects in SMAD-dependent
signalling has been linked to hypertension and cardiac pathologies,
primarily through their association with TGF-β pathways [27,34].
Therefore, abnormal miR-199a-5p expression will reflect perturbations
in these pathways although it remains uncertain whether its altered
expression is the cause or result of dysregulated signalling.
Although miR-199a-5p has been previously linked with CVD, only
one other study to our knowledge has specifically reported miR-199a-
5p as a circulating serum marker of hypertension. A retrospective
human study by Hromadnikova et al. (2016) found that down-regula-
tion of miR-199a-5p in maternal peripheral blood was associated with
gestational hypertension, preeclampsia, and intrauterine growth re-
striction [41]. As the most directly comparable study to ours, it is no-
table that the inverse correlation of miR-199a-5p with blood pressure
found in that study agrees with our current findings for patients with
MTHFR 677TT genotype. Interestingly, the authors also concluded that
Fig. 4. Network Analysis of miR-199a-5p Interactions.
(a) miRanda predicted pairing of three putative target regions in 3’ UTR of SMAD4 and miR-199-5p. (b) qRT-PCR shows that over-expression of miR-199a-5p in
HUVEC cells causes SMAD4 and VEGFA levels to be significantly decreased. Significance was assessed by Student two tailed t-test. (P-values: *p < .05,
***p < .001). (c) Inverse correlation between miR-199-5p and SMAD4 expression in human aortic valvular endothelial cells. Public Dataset ID: GSE26953; array
data from Holliday et al. [37]. Significance was assessed by Pearson's two tailed correlation (P-values: *p < .05). (a.u.: arbitrary units) (d) Network analysis using
miRTarbase [20] reveals that miR-199a-5p impacts upon SMAD4 as well as several other targets many of which are known to contribute to hypertension. Likewise,
SMAD4 is regulated by several miRNAs. Accession ID: MIRT007013 [miRNA, hsa-miR-199a-5p:: SMAD4, target gene].
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dysregulation of miR-199a-5p may be linked to epigenetic changes in-
duced by pregnancy-related complications. This finding has relevance
for our current study as MTHFR is a key enzyme in the folate meta-
bolism pathway and therefore influences DNA methylation. Indeed,
aberrant hypermethylation and expression of genes involved in DNA
methylation has been reported in patients with the variant MTHFR
677TT genotype [42–44] and epigenetic mechanisms are known to
contribute to hypertension [45,46]. If epigenetic regulation of miR-
199a-5p is similarly affected, this may explain why the correlation of
miR-199a-5p with blood pressure was only apparent in the TT group of
patients. Furthermore, it might explain why changes in miR-199a-5p
correlated with blood pressure reduction in the TT patients who re-
sponded to riboflavin treatment. Significantly, there is evidence from
COPD studies that miR-199a-5p is indeed regulated by methylation
status of its promoter [47], so it is tempting to speculate that its ex-
pression is affected by aberrant DNA methylation in patients with the
MTHFR 677TT genotype. Altered expression of miR-199a-5p in TT re-
sponders may be owing to riboflavin altering the epigenetic regulation
of miR-199a-5p, which in turn may then help reduce blood pressure in
this cohort through regulation of genes such as SMAD4. Further work in
our lab intends to investigate the link between miR-199a-5p and its
epigenetic regulation, which may help explain why it displays differ-
ential expression in the different disease models discussed above.
In summary, the design of our previous randomized trial which
generated the samples for the current analysis provided a unique op-
portunity to investigate the association between miRNA expression and
blood pressure in premature CVD patients with a genetic risk factor for
hypertension. Consequently, this is the first study to correlate miR-
199a-5p expression with blood pressure in patients with the MTHFR
677TT genotype. Furthermore, this study also provides evidence that
changes in miR-199a-5p expression are associated with changes in
blood pressure in this at-risk group. It is of course important to ac-
knowledge that this study has only investigated a small number of
samples, so similar testing of a larger patient cohort would be required
to definitively state that miR-199a-5p is a true marker of hypertension
in patients with the MTHFR 677TT genotype. It would also be useful to
include a cohort of patients carrying the polymorphism in hetero-
zygosity (C/T) and perform the same evaluations to further understand
the role of miR-199a-5p in hypertension. Nevertheless, even with a
relatively small sample set, it is encouraging that our data led us to
highlight miR-199a-5p, a miRNA which others have associated with
hypertension in independent studies. Furthermore, in identifying
SMAD4 as a probable target, we have also proposed a plausible biolo-
gical pathway whereby miR-199a-5p could contribute to hypertensive
mechanisms. We can therefore speculate that miR-199a-5p plays an
important role in the pathogenesis of CVD, particularly in at-risk in-
dividuals. Although further investigation is needed to unravel the
complex genetic mechanisms involved in the development of essential
hypertension, this study demonstrates the value of miRNA serum pro-
filing as an analytical tool to investigate and understand the underlying
pathogenesis of CVD.
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